NCT02166554

Brief Summary

The purpose of this study was to determine whether the new crosslinked hyaluronan hydrogel was safe to use, and was effective for the prevention/reduction of adhesion formation following gynecological surgery

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
216

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jun 2011

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 13, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 18, 2014

Completed
Last Updated

June 18, 2014

Status Verified

June 1, 2014

Enrollment Period

1.8 years

First QC Date

June 13, 2014

Last Update Submit

June 16, 2014

Conditions

Keywords

AdhesionsHyaluronanGynaecological surgeryClinical outcomes

Outcome Measures

Primary Outcomes (1)

  • The adhesion incidence under moderate/severe category

    The patient percentage with modified American Fertility Society (mAFS) score (ovaries and tubes) more than 4 points.

    9 weeks following primary laparoscopic gynecological surgery

Secondary Outcomes (8)

  • modified American Fertility Society (mAFS) score

    9 weeks following primary laparoscopic gynecological surgery

  • Adhesion extent

    9 weeks following primary laparoscopic gynecological surgery

  • Adhesion severity

    9 weeks following primary laparoscopic gynecological surgery

  • The adhesion incidence under moderate/severe category

    9 weeks following primary laparoscopic gynecological surgery

  • modified American Fertility Society (mAFS) score

    9 weeks following primary laparoscopic gynecological surgery

  • +3 more secondary outcomes

Study Arms (2)

Control Arm

PLACEBO COMPARATOR

Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery

Other: Saline

Cross-linked Hyaluronan Hydrogel Arm

EXPERIMENTAL

HyaRegen

Device: Cross-linked Hyaluronan Hydrogel

Interventions

SalineOTHER

On the day of initial surgery

Control Arm

On the day of the initial surgery

Also known as: HyaRegen, Self Cross-linked Hyaluronan Gel
Cross-linked Hyaluronan Hydrogel Arm

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female.
  • Aged 18-45 years.
  • Been scheduled for removal of myomas, ovary cysts, endometriotic cysts or adhesions.
  • Been willing to comply with all aspects of the treatment and evaluation schedule.
  • Agreed to a second-look laparoscopic procedure to assess and lyse any adhesions formed at 9 weeks following the primary surgery.
  • Provided voluntary written informed consent.

You may not qualify if:

  • Acute or severe infection.
  • Autoimmune diseases such as diabetes etc.
  • Abnormal liver/renal and cardiovascular function
  • Abnormal blood coagulation
  • Medical histories of peripheral vascular disease, alcohol or drug abuse, and mental illness.
  • Known or suspected intolerance or hypersensitivity to hyaluronan or its derivatives.
  • Concurrent use of systemic antiinflammatory drugs.
  • Clinical evidence of cancer.
  • Use of anticoagulant, fibrin glue, other thrombogenic agents, or any other anti-adhesion agent during the procedure.
  • Concurrent peritoneal grafting or tubal implantation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Beijing Chao-Yang Hospital

Beijing, Beijing Municipality, 100020, China

Location

China-Japan Friendship Hospital

Beijing, Beijing Municipality, 100029, China

Location

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Location

Beijing Hospital

Beijing, Beijing Municipality, 100730, China

Location

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

Location

The Third Xiangya Hospital

Changsha, Hunan, 410013, China

Location

Qilu Hospital

Jinan, Shandong, 250012, China

Location

Related Publications (1)

  • Liu C, Lu Q, Zhang Z, Xue M, Zhang Y, Zhang Y, Wang H, Li H, Zhou Y, Zhang Z, Li W; HyaRegen Adhesion Study Group. A Randomized Controlled Trial on the Efficacy and Safety of a New Crosslinked Hyaluronan Gel in Reducing Adhesions after Gynecologic Laparoscopic Surgeries. J Minim Invasive Gynecol. 2015 Jul-Aug;22(5):853-63. doi: 10.1016/j.jmig.2015.04.011. Epub 2015 Apr 20.

MeSH Terms

Conditions

MyomaTissue Adhesions

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsCicatrixFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Zhenyu Zhang, MD, PhD

    Beijing Chao Yang Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2014

First Posted

June 18, 2014

Study Start

June 1, 2011

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

June 18, 2014

Record last verified: 2014-06

Locations